Ultra‑ high‑risk chronic lymphocytic leukemia – characteristics and treatment options
Authors:
D. Lysák; P. Jindra
Authors place of work:
Hematologicko‑onkologické oddělení FN Plzeň, přednosta prim. MU Dr. Pavel Jindra, Ph. D.
Published in the journal:
Vnitř Lék 2013; 59(10): 887-894
Category:
Review
Summary
Chronic lymphocytic leukemia (CLL) is the most common form adult leukemia in western world. The disease is typically characterized by heterogeneous clinical behavior ranging from indolent course to rapidly progressive disease. Using clinical and biological factors we can stratify patients with CLL and prospectively identify those who can be expected unfavorable course. There is a special group known as ultra high‑risk chronic lymphocytic leukemia with an extremely poor prognosis. These are about 10– 15% of all patients with CLL. They do not respond to standard treatment and their survival is short with a median of 2– 3 years. For high‑risk patients are considered: patients with a proven TP53 defect, refractory to purine analogues or with early relapse after chemoimmunotherapy based on fludarabine (≤ 24 months). While the standard 1st line treatment protocol in younger patients is chemoimmunotherapy FCR, in case of ultra‑ high‑risk CLL other methods like allogeneic hematopoietic stem cell transplantation or clinical trials testing the new drugs should be considered. In particular, allogeneic hematopoietic stem cell transplantation is a very promising treatment modality that offers long‑term disease control and cure regardless of the unfavorable CLL subtype. Transplantation treatment should be therefore considered in all younger patients with ultra‑ high‑risk CLL, who should be without delay referred to a center for intensive hematological treatment.
Key words:
chronic lymphocytic leukemia – high‑risk cytogenetics – allogeneic transplantation
Zdroje
1. Dores GM, Anderson WF, Curtis RE et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol 2007; 139: 809– 819.
2. Eichhorst B, Dreyling M, Robak T et al. ESMO Guidelines Working Group. Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow‑up. Ann Oncol 2011; 22 (Suppl 6): vi50– vi54.
3. Keating MJ, O’Brien S, Albitar M et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4079– 4088.
4. Eichhorst BF, Busch R, Hopfinger G et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first‑line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885– 891.
5. Zenz T, Gribben JG, Hallek M et al. Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood 2012; 119: 4101– 4107.
6. Tam CS, O’Brien S, Wierda W et al. Long‑term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112: 975– 980.
7. Abrisqueta P, Pereira A, Rozman C et al. Improving survival in patients with chronic lymphocytic leukemia (1980– 2008): The hospital clinic of Barcelona experience. Blood 2009; 114: 2044– 2050.
8. Hallek M, Fischer K, Fingerle‑ Rowson G et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open‑ label, phase 3 trial. Lancet 2010; 376: 1164– 1174.
9. Badoux XC, Keating MJ, Wang X et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 2011; 117: 3016– 3024.
10. Wierda W, O’Brien S, Faderl S et al. A retrospective comparison of three sequential groups of patients with Recurrent/ Refractory chronic lymphocytic leukemia treated with fludarabine‑based regimens. Cancer 2006; 106: 337– 345.
11. Motyckova M, Zak P, Vroblova V et al. Prognostic markers in chronic lymphocytic leukemia. Vnitř Lék 2011; 57: 847– 857.
12. Smolej L, Saudkova L, Spacek M et al. ZAP‑ 70 in B‑ cell chronic lymphocytic leukemia: Clinical significance and methods of detection. Vnitř Lék 2006; 52: 1194– 1199.
13. Dohner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910– 1916.
14. Zent CS, Kay NE. Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: The mayo clinic approach. Leuk Lymphoma 2011; 52: 1425– 1434.
15. Zenz T, Eichhorst B, Busch R et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 4473– 4479.
16. Stilgenbauer S, Zenz T. Understanding and managing ultra high‑risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2010; 2010: 481– 488.
17. Hallek M, Fingerle‑ Rowson G, Fink A et al. First‑line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): Results of a randomized phase III trial on behalf of an international group of investigators and the German CLL study group. ASH Annual Meeting Abstracts 2009; 114: Abstract 535.
18. Badoux XC, Keating MJ, Wierda WG. What is the best frontline therapy for patients with CLL and 17p deletion? Curr Hematol Malig Rep 2011; 6: 36– 46.
19. Shanafelt TD, Witzig TE, Fink SR et al. Prospective evaluation of clonal evolution during long‑term follow‑up of patients with untreated early‑stage chronic lymphocytic leukemia. J Clin Oncol 2006; 24: 4634– 4641.
20. Pospisilova S, Gonzales D, Malcikova J et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 2012; 26: 1458– 1461.
21. Zenz T, Mertens D, Kuppers R et al. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10: 37– 50.
22. Rossi D, Rasi S, Fabbri G et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012; 119: 521– 529.
23. Oscier DG, Rose‑Zerilli MJ, Winkelmann N et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 2013; 121: 468– 475.
24. Rossi D, Rasi S, Spina V et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013; 121: 1403– 1412.
25. Rossi D, Fangazio M, Rasi S et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild‑type chronic lymphocytic leukemia. Blood 2012; 119: 2854– 2862.
26. Zenz T, Bush R, Fink A et al. Genetics of Patients with F‑ Refractory CLL or Early Relapse After FC or FCR: Results From the CLL8 Trial of the GCLLSG ASH Annual Meeting Abstracts 2010; 116: 2427.
27. Panovská A, Smolej L, Lysák D et al. The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab. Eur J Haematol 2013; 90: 479– 485.
28. Boettcher S, Fischer K, Stilgenbauer S et al. Quantitative MRD assessments predict progression free survival in CLL patients treated with fludarabine and cyclophosphamide with or without rituximab – a prospective analysis in 471 patients from the randomized GCLLSG CLL8 trial. ASH Annual Meeting Abstracts 2008; 112: Abstract 326.
29. Keating MJ, O‘Brien S, Albitar M et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4079– 4088.
30. Dreger P, Dohner H, Ritgen M et al. Allogeneic stem cell transplantation provides durable disease control in poor‑ risk chronic lymphocytic leukemia: Long‑term clinical and MRD results of the german CLL study group CLL3X trial. Blood 2010; 116: 2438– 2447.
31. Dreger P, Corradini P, Kimby E et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: The EBMT transplant consensus. Leukemia 2007; 21: 12– 17.
32. Smolej L, Prochazka V, Spacek M et al. Guidelines for alemtuzumab treatment in chronic lymphocytic leukaemia (CLL). Vnitř Lék 2012; 58: 232– 236.
33. Doubek M, Jungova A, Brejcha M et al. Alemtuzumab in chronic lymphocytic leukemia treatment: Retrospective analysis of outcome according to cytogenetics. Vnitř Lék 2009; 55: 549– 554.
34. Stilgenbauer S, Zenz T, Winkler D et al. Subcutaneous alemtuzumab in fludarabine‑ refractory chronic lymphocytic leukemia: Clinical results and prognostic marker analyses from the CLL2H study of the german chronic lymphocytic leukemia study group. J Clin Oncol 2009; 27: 3994– 4001.
35. Lozanski G, Heerema N, Flinn I et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103: 3278– 3281.
36. Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (CAMPATH‑ 1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554– 3561.
37. Sher T, Miller KC, Lawrence D et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high‑risk cytogenetics. Leuk Lymphoma 2010; 51: 85– 88.
38. Wierda WG, Kipps TJ, Mayer J et al. Hx‑ CD20– 406 Study Investigators. Ofatumumab as single‑agent CD20 immunotherapy in fludarabine‑ refractory chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 1749– 1755.
39. Wierda WG, Kipps TJ, Dürig J et al. 407 Study Investigators. Chemoimmunotherapy with O‑ FC in previously untreated patients with chronic lymphocytic leukemia. Blood 2011; 117: 6450– 6458.
40. Bowen DA, Call TG, Jenkins GD et al. Methylprednisolone‑ rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007; 48: 2412– 2417.
41. Smolej L, Doubek M, Panovská A et al. Rituximab in combination with high‑ dose dexamethasone for the treatment of relapsed/ refractory chronic lymphocytic leukemia. Leuk Res 2012; 36: 1278– 1282.
42. Pettitt AR, Jackson R, Carruthers S et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol 2012; 30: 1647– 1655.
43. Stilgenbauer S, Cymbalista F, Leblond V et al. Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High‑Risk CLL: Updated Results From a Phase II Study of the Gcllsg and fcgcll/ MW. ASH Annual Meeting Abstracts 2012; 120: Abstract 716.
44. Köppler H, Fuss H, Hurtz HJ et al. Bendamustine plus mitoxantrone for relapsed/ refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG). Br J Hematol 2012; 158: 238– 241.
45. Visco C, Finotto S, Pomponi F et al. The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/ refractory cytogenetically high‑risk patients with chronic lymphocytic leukemia. Am J Hematol 2013; 88: 289– 293.
46. Courtre SE, Leonard JP, Furman RR et al. Combinations of the Selective Phosphatidylinositol 3- Kinase‑ Delta (PI3Kdelta) Inhibitor GS‑ 1101 (CAL‑ 101) with Rituximab and/ or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study. ASH Annual Meeting Abstracts 2012; 120: Abstract 191.
47. Burger JA, Keating MJ, Wierda WG et al. The Btk Inhibitor Ibrutinib (PCI‑ 32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High‑Risk Chronic Lymphocytic Leukemia (CLL) Patients. ASH Annual Meeting Abstracts 2012; 120: Abstract 187.
48. Michallet M, Dreger P, Sutton L et al. Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: Results of european intergroup randomized trial comparing autografting versus observation. Blood 2011; 117: 1516– 1521.
49. Schetelig J, van Biezen A, Brand R et al. Allogeneic hematopoietic stem‑ cell transplantation for chronic lymphocytic leukemia with 17p deletion: A retrospective european group for blood and marrow transplantation analysis. J Clin Oncol 2008; 26: 5094– 5100.
50. Dreger P, Brand R, Milligan D et al. Reduced‑ intensity conditioning lowers treatment‑related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: A population‑ matched analysis. Leukemia 2005; 19: 1029– 1033.
51. Ritgen M, Stilgenbauer S, von Neuhoff N et al. Graft‑ versus‑ leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy‑chain gene status: Implications of minimal residual disease measurement with quantitative PCR. Blood 2004; 104: 2600– 2602.
52. Richardson SE, Khan I, Eawstron A et al. Risk‑stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia. Br J Haematol 2013; 160: 640– 648.
53. Michallet M, Sobh M, Milligan D et al. The impact of HLA matching on long‑term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: A retrospective study from the EBMT registry. Leukemia 2010; 24: 1725– 1731.
54. Michallet M, Socié G, Mohty M et al. Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long‑term prospective multicenter study. Exp Hematol 2013; 41: 127– 133.
55. Machaczka M, Johansson JE, Remberger M et al. Allogeneic hematopoietic stem cell transplant with reduced‑ intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T‑ cell engraftment 3 months after transplant predict survival? Leuk Lymphoma 2012; 53: 1699– 1705.
56. Khouri IF, Bassett R, Poindexter N et al.Nonmyeloablative allogeneic stem cell transplantation in relapsed/ refractory chronic lymphocytic leukemia: long‑term follow‑up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer 2011; 117: 4679– 4688.
57. Sorror ML, Storer BE, Sandmaier BM et al. Five‑year follow‑up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008; 26: 4912– 4920.
Štítky
Diabetology Endocrinology Internal medicineČlánok vyšiel v časopise
Internal Medicine
2013 Číslo 10
Najčítanejšie v tomto čísle
- Methods of skin microcirculation assessment
- Tricuspid valve infective endocarditis in intravenous drug abuser
- The current approach to the treatment of the patients with metastatic colorectal cancer
- Management of dyslipidaemias – present and future. Guidelines of the Angiology Section of the Slovak Medical Chamber (2013)